CA3180559A1 - Administration of cebp-beta antagonist and methods of use - Google Patents

Administration of cebp-beta antagonist and methods of use Download PDF

Info

Publication number
CA3180559A1
CA3180559A1 CA3180559A CA3180559A CA3180559A1 CA 3180559 A1 CA3180559 A1 CA 3180559A1 CA 3180559 A CA3180559 A CA 3180559A CA 3180559 A CA3180559 A CA 3180559A CA 3180559 A1 CA3180559 A1 CA 3180559A1
Authority
CA
Canada
Prior art keywords
patient
pharmaceutical composition
administered
administration
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180559A
Other languages
English (en)
French (fr)
Inventor
Barry Jay Kappel
Gene Merutka
Jimmy Andrew Rotolo
Robert E. Michel
Alice Susannah BEXON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapience Therapeutics Inc
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of CA3180559A1 publication Critical patent/CA3180559A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3180559A 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use Pending CA3180559A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063041989P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202063041990P 2020-06-21 2020-06-21
US202063041991P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US63/041,986 2020-06-21
US63/041,990 2020-06-21
US63/041,989 2020-06-21
US63/041,991 2020-06-21
US63/041,988 2020-06-21
US202163172560P 2021-04-08 2021-04-08
US63/172,560 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (1)

Publication Number Publication Date
CA3180559A1 true CA3180559A1 (en) 2021-12-30

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180559A Pending CA3180559A1 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Country Status (17)

Country Link
US (1) US20230218717A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7880618B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027054A (cg-RX-API-DMAC7.html)
CN (1) CN115768458A (cg-RX-API-DMAC7.html)
AU (1) AU2021297172B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4168033T3 (cg-RX-API-DMAC7.html)
ES (1) ES3066151T3 (cg-RX-API-DMAC7.html)
FI (1) FI4168033T3 (cg-RX-API-DMAC7.html)
IL (1) IL299104A (cg-RX-API-DMAC7.html)
MX (1) MX2022016478A (cg-RX-API-DMAC7.html)
NZ (1) NZ795026A (cg-RX-API-DMAC7.html)
PT (1) PT4168033T (cg-RX-API-DMAC7.html)
WO (1) WO2021262604A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213167B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119997967A (zh) * 2022-10-07 2025-05-13 智慧疗法有限公司 C/EBP-β拮抗剂和免疫调节剂的使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
EP4694911A2 (en) * 2023-04-13 2026-02-18 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228642A (zh) * 2013-02-22 2016-01-06 纽约市哥伦比亚大学理事会 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法
CA2983030A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
WO2018152446A2 (en) 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
PT3737399T (pt) 2018-01-03 2023-09-04 Sapience Therapeutics Inc Variantes do péptido atf5 e as respetivas utilizações
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Also Published As

Publication number Publication date
ES3066151T3 (en) 2026-05-11
EP4168033A4 (en) 2024-06-19
AU2021297172A1 (en) 2023-01-19
KR20230027054A (ko) 2023-02-27
EP4168033B1 (en) 2026-02-25
FI4168033T3 (fi) 2026-04-07
US20230218717A1 (en) 2023-07-13
IL299104A (en) 2023-02-01
PT4168033T (pt) 2026-03-24
BR112022025880A2 (pt) 2023-01-10
JP7880618B2 (ja) 2026-06-26
AU2021297172B2 (en) 2025-01-30
DK4168033T3 (da) 2026-05-11
MX2022016478A (es) 2023-02-01
ZA202213167B (en) 2026-03-25
EP4168033A2 (en) 2023-04-26
NZ795026A (en) 2026-03-27
JP2023531683A (ja) 2023-07-25
WO2021262604A3 (en) 2022-02-17
WO2021262604A2 (en) 2021-12-30
CN115768458A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
CA2759129C (en) Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2021297172B2 (en) Administration of CEBPβ antagonist and methods of use
US12528846B2 (en) BH4 stabilized peptides and uses thereof
CN111263635A (zh) Nr4a1配体、药物组合物以及相关使用方法
JP2023531683A5 (cg-RX-API-DMAC7.html)
IL323919A (en) Administration of a beta-catenin antagonist and methods of use
US20240358701A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2024006207A1 (en) An n-terminal domain androgen receptor inhibitor and uses thereof
US20230165933A1 (en) Peptides containing a pcna interacting motif for use in the treatment of solid cancer
WO2024077297A2 (en) Use of c/ebp-beta antagonist and immunomodulator
AU2017248264A1 (en) Compositions and methods for treating pancreatitis and pain with death receptor agonists
EP4694912A2 (en) Use of beta-catenin antagonist and immunomodulator
WO2025110250A1 (ja) 改変mfg-e8タンパク質
HK40022745A (en) Nr4a1 ligands, pharmaceutical compositions, and related methods of use
EA041148B1 (ru) Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
HK1167347B (en) Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250618

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250618

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250618

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250826

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250826

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250826

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250827

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20251027

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20260303

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260303

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260303

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260519

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260519